Treatment of esophagogastric junction carcinoma: an unsolved debate.
The incidence of esophagogastric junction adenocarcinoma (AEG) is increasing worldwide. Barrett's esophagus (BE) associated with dysplasia is the main risk factor for the development of cancer. Currently, screening programs to individuate and eradicate BE represent the best way to reduce AEG cancer. Several endoscopic approaches are here discussed. Surgical strategies for different types of AEG cancer are now fairly standardized, and multidisciplinary strategies using chemotherapy or chemoradiotherapy may improve the outcome of these patients. Here we briefly discuss the keypoints, main topics, and critical issues, according to accumulating evidence and taking into account our own experience.
Michele Orditura, Ferdinando De Vita, Fortunato Ciardiello, Division of Medical Oncology, Department of Internal and Experimental Medicine "F. Magrassi", School of Medicine, Second University of Naples, 80131 Naples, Italy.
Michele
M
Orditura
Michele Orditura, Ferdinando De Vita, Fortunato Ciardiello, Division of Medical Oncology, Department of Internal and Experimental Medicine "F. Magrassi", School of Medicine, Second University of Naples, 80131 Naples, Italy.
Gennaro
G
Galizia
Michele Orditura, Ferdinando De Vita, Fortunato Ciardiello, Division of Medical Oncology, Department of Internal and Experimental Medicine "F. Magrassi", School of Medicine, Second University of Naples, 80131 Naples, Italy.
Eva
E
Lieto
Michele Orditura, Ferdinando De Vita, Fortunato Ciardiello, Division of Medical Oncology, Department of Internal and Experimental Medicine "F. Magrassi", School of Medicine, Second University of Naples, 80131 Naples, Italy.
Ferdinando
F
De Vita
Michele Orditura, Ferdinando De Vita, Fortunato Ciardiello, Division of Medical Oncology, Department of Internal and Experimental Medicine "F. Magrassi", School of Medicine, Second University of Naples, 80131 Naples, Italy.
Fortunato
F
Ciardiello
D000230:Adenocarcinoma / Q000453:epidemiology / Q000473:pathology / Q000601:surgery*; D001471:Barrett Esophagus / Q000453:epidemiology; D059186:Chemoradiotherapy, Adjuvant; D017024:Chemotherapy, Adjuvant; D004938:Esophageal Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000601:surgery*; D016629:Esophagectomy; D004943:Esophagogastric Junction / Q000473:pathology / Q000601:surgery*; D006801:Humans; D020360:Neoadjuvant Therapy; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome
Barrett’s esophagus; Chemoradiotherapy; Chemotherapy; Endoscopic resection; Esophagogastric junction adenocarcinoma; Surgery